Alnylam Pharma (ALNY) Misses Q2 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $236.22 +3.02%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($2.03), $0.42 worse than the analyst estimate of ($1.61). Revenue for the quarter came in at $224.82 million versus the consensus estimate of $255.87 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
- S&P 500 may pull back before midterms, but Citi says buy the dip
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
